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Cortical cholinergic deﬁciency is prominent in Alzheimer’s disease (AD), and published ﬁndings of diminished pupil ﬂash response
in AD suggest that this deﬁciency may extend to the visual cortical areas and anterior eye. Pupillometry is a low-cost, noninvasive
technique that may be useful for monitoring cholinergic deﬁcits which generally lead to memory and cognitive disorders. The aim
of the study was to evaluate pupillometry for early detection of AD by comparing the pupil ﬂash response (PFR) in AD (N = 14) and
cognitively normal healthy control (HC, N = 115) participants, with the HC group stratiﬁed according to high (N = 38) and low
(N = 77) neocortical amyloid burden (NAB). Constriction phase PFR parameters were signiﬁcantly reduced in AD compared to
HC (maximum acceleration p < 0 05, maximum velocity p < 0 0005, average velocity p < 0 005, and constriction amplitude
p < 0 00005). The high-NAB HC subgroup had reduced PFR response cross-sectionally, and also a greater decline
longitudinally, compared to the low-NAB subgroup, suggesting changes to pupil response in preclinical AD. The results
suggest that PFR changes may occur in the preclinical phase of AD. Hence, pupillometry has a potential as an adjunct for
noninvasive, cost-eﬀective screening for preclinical AD.

1. Introduction
The ocular pupil controls retinal illumination and responds
dynamically to a bright ﬂash of light by rapid constriction
followed by redilation (Figure 1). Pupillometry investigates
this response by delivering a ﬂash of light into the eye and accurately detecting and measuring pupil size changes over time.
Pupil size and response are controlled by the opposing
action of the sphincter and dilator muscles of the iris. The

constriction phase of the pupil response (Figure 1) is primarily driven by the cholinergic system [1], with acetylcholine
(ACh) being the neurotransmitter involved in projections
between the Edinger-Westphal nucleus, ciliary ganglion,
and sphincter muscle [2]. Thus, pupillometry provides a
practical, noninvasive approach with which to evaluate
cholinergic deﬁciency.
Pupillometry has been used to identify a cholinergic
deﬁciency in a number of disorders including Alzheimer’s

2

Journal of Ophthalmology

2

5
D1
4.5
4

Velocity (mm/sec)

Pupil diameter (mm)

Constriction Initial
phase
dilation phase

Constriction amplitude

3.5
3
D2
2.5

0

0.5

1

1.5

2

2.5

0
‒2

‒6

3

Maximum constriction velocity

‒4
0

0.5

1
1.5
2
Time after stimulus (sec)

Time after stimulus (sec)
(a)

2.5

3

(b)

Acceleration (mm/sec2)

25
15
5
‒5
‒15

Maximum constriction acceleration

‒25
‒35

0

0.5

1
1.5
2
Time after stimulus (sec)

2.5

3

(c)

Figure 1: Illustration of pupil ﬂash response and parameters measured. (a) Pupil diameter over time after stimulus at time zero. (b) Pupil
velocity (rate of change of pupil diameter). (c) Pupil acceleration (rate of change of velocity). The constriction phase lasts from stimulus to
minimum pupil size; parameters calculated during this phase are the constriction amplitude, maximum and average constriction velocity,
and maximum constriction acceleration.

disease (AD) [3–8] and Parkinson’s disease [5, 9]. As the
primary neurotransmitter deﬁcit in AD is ACh [10–12], the
constriction phase of the pupil ﬂash response (PFR) has
gained interest for evaluating cholinergic deﬁciency and for
early detection, diagnosis, and monitoring of AD. The majority of study results to date indicate a slower and reduced pupil
response in AD, with reduced velocities, accelerations, and
constriction amplitude, and increased latencies. The work
of Ferrario et al. [6] on only constriction acceleration stands
in contrast, possibly due to diﬀerent methodology and participant selection. Some studies indicate a faster recovery after
stimulus in AD, despite slower constriction and dilation
velocities, probably due to the reduced amplitude [3, 13].
Our prior study [8] found a weaker pupil constriction
response in AD, consistent with the hypothesis of a cholinergic deﬁcit in the peripheral parasympathetic pathway in AD.
Signiﬁcant diﬀerences were found between AD and cognitively normal healthy control (HC) participants in 10 diﬀerent calculated PFR parameters, with the greatest diﬀerences
coming from the constriction phase: maximum constriction
acceleration, maximum constriction velocity, mean constriction velocity, and constriction amplitude. These promising
preliminary results warranted further investigation into
whether pupil response changes occur early in AD, possibly providing a test for early detection or monitoring of
the disease.
AD is characterized clinically by a progressive decline
in memory, learning, and executive function and

neuropathologically by the presence of cerebral extracellular
amyloid deposits (plaques), intracellular neuroﬁbrillary
tangles, and cerebral (in particular hippocampal) atrophy.
In addition to the debilitating symptoms endured by AD
patients, the disease imposes a huge social and economic
burden on society [14].
AD cognitive symptoms arise only after extensive, irreversible neural deterioration has already occurred. As a
result, diagnosis is usually made late in the disease process,
limiting both the eﬃcacy of available treatments and the
evaluation of new treatments. Biomarkers for early detection of AD include cerebrospinal ﬂuid concentrations of
beta-amyloid (Aβ), total tau and phosphorylated tau peptides [15–18], and brain Aβ plaque burden imaged using
positron emission tomography (PET) [16, 18–20]. Research
demonstrates that plaque burden can be detected over 20
years before cognitive symptoms begin [21]. However, while
these are valuable diagnostic and secondary screening biomarkers, they are not suitable as primary screening technologies for AD. A screening process that could provide early,
accurate diagnosis or a prognosis of AD would enable
earlier intervention, facilitate cost-eﬀective screening into
treatment trials, and allow current and future treatments
to be more eﬀective.
The present study investigated constriction phase pupil
response in AD and HC participants, with a particular focus
on PFR changes in preclinical AD as determined by high
neocortical amyloid burden (NAB).
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2. Materials and Methods
2.1. Participants. Participants for the study were recruited
from the Australian Imaging, Biomarkers, and Lifestyle
(AIBL) study of ageing in Australia. The AIBL study has
two sites: Melbourne (Victoria) and Perth (Western
Australia). The pupillometry study was conducted only at
the Perth site. A previous report details the AIBL study
design and baseline cohort [22]. Brieﬂy, the AIBL study integrates data from neuroimaging, biomarkers, lifestyle, clinical,
and neuropsychological domains for eligible volunteers older
than 60 years who are ﬂuent in English. AIBL classiﬁes participants into 3 groups: (1) individuals meeting the criteria
for AD based on the NINCDS-ADRDA (National Institute
of Neurological and Communicative Disorders and StrokeAlzheimer’s Disease and Related Disorders Association)
[23], (2) individuals meeting the criteria for mild cognitive
impairment [24, 25], and (3) cognitively normal healthy
control individuals.
The following were part of the AIBL exclusion criteria: a
history of non-AD dementia, schizophrenia, bipolar disorder, signiﬁcant current (but not past) depression (geriatric
depression scale above 5/15), Parkinson’s disease, cancer
(other than basal cell skin carcinoma) within the last 2
years, symptomatic stroke, uncontrolled diabetes, diagnosed
obstructive sleep apnoea, or current regular alcohol use
exceeding 2 standard drinks per day for women or 4 per
day for men.
AIBL participants were excluded from the pupil response
study if they did not have PET data available; if they had
pupillary malformations, severe cataract, self-reported history of glaucoma in either eye, penetrating eye wounds to
both eyes, and eye surgery to both eyes that involved the
muscle; if they used cholinesterase inhibitors or prescribed
ocular medications; or if they were unable to complete the
task without excessive blinking.
All participants provided written informed consent, and
all PFR procedures were approved by the Hollywood
Private Hospital Research Ethics Committee according to
the Helsinki Declaration. Approval for the parent AIBL study
was obtained from the Austin Health Human Research
Ethics Committee, the Hollywood Private Hospital Research
Ethics Committee, the St. Vincent Hospital Research
Ethics Committee, and the Edith Cowan University Human
Research Ethics Committee.
The present study draws upon data generated from the
AIBL study, including neuroimaging and genetic test results.
The methodology for these AIBL procedures is reported
elsewhere [22] and summarized below.
2.2. Neuroimaging. Neuroimaging methodology is reported
in more detail elsewhere [26]. Brieﬂy, participants were
neuroimaged for the presence of ﬁbrillar brain Aβ using
PET with 2 diﬀerent radiotracers: 11C-Pittsburgh compound
B (PiB) and 18F-ﬂutemetamol (FLUTE). Previous reports
describe the PET methodology for each tracer in detail
[20, 27]. For semiquantitative analysis, a volume of interest
template was applied to the summed and spatially normalized PET images to obtain a standardized uptake value
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(SUV). The images were then scaled to the SUV of each
tracer’s recommended reference region to generate a tissue
ratio termed SUV ratio (SUVR). A global measure of NAB
was computed using the mean SUVR in the frontal, superior
parietal, lateral temporal, occipital, and anterior and posterior cingulate regions of the brain. For PiB, the SUV was normalized to the cerebellar cortex, whereas the pons was used as
the reference region for FLUTE [28]. SUVR was stratiﬁed
into a dichotomous variable classiﬁed as high or low based
on neuropathologically validated thresholds for each tracer.
We considered participants who underwent FLUTE imaging
to have high NAB when the SUVR was 0.62 or higher [28],
and for PiB imaging, when the SUVR was 1.4 or higher [29].
2.3. Genotyping. APOE genotyping was performed according
to the following protocol: fasting blood samples were
obtained using standard venepuncture of the antecubital vein
and collected into EDTA tubes containing prostaglandin E1
(PGE: 33.3 ng/ml; Sapphire Bioscience, NSW, Australia) to
prevent platelet activation. Extraction of DNA from 5 ml of
whole blood was undertaken using QIAamp DNA Blood
Maxi Kits (Qiagen, Hilden, Germany) as per the manufacturer’s instructions. Speciﬁc TaqMan® (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) genotyping assays were
used for ascertaining APOE genotype (rs7412, assay ID:
C____904973_10; rs429358, assay ID: C___3084793_20),
which were performed on a QuantStudio 12K Flex™
real-time PCR system (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) using the TaqMan GTXpress™ Master Mix
(Thermo Fisher Scientiﬁc, Waltham, MA, USA).
2.4. System of Pupillometry. A record of the pupil’s response
to a ﬂash of light was collected for each participant using a
commercial pupillometer. The PFR was collected using a
NeurOptics™ VIP™-200 Pupillometer. This is a commercial,
monocular device providing fully automated operation and
calculation of response parameters. The device produces a
white ﬂash stimulus and then measures the pupil size for
5 seconds using infrared illumination. The video frame
rate is 33 Hz, the stimulus/pulse intensity is 180 μW, and
the stimulus/pulse duration is 31 ms. The pupillometer
produces diﬀuse light over the whole visual ﬁeld.
The room was darkened for 2 minutes prior to testing.
The test was practiced once before recording. Occasionally,
an extra trial was needed to achieve a recording without
blinks or artefacts. Data was rejected if artefacts were present.
The right eye was used for all participants, except where there
was injury or pathology to the right eye only or a suitable
pupil response could not be obtained with the right eye, in
which case the left eye was used (N = 1). The pupillometer
provided automatic calculation of the following pupil
response parameters: resting pupil diameter (D1, mm), minimum pupil diameter (D2, mm), average constriction velocity (CV, mm/sec), maximum constriction velocity (MCV,
mm/sec), and constriction amplitude (AMP, mm), which
was calculated as the diﬀerence between resting pupil diameter and minimum pupil diameter (D1 − D2, mm). A record of
the pupil’s diameter as a function of time was exported from
the pupillometer. From this record, maximum constriction
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Table 1: Demographics and descriptive PFR analysis for HC and AD groups, with ANOVA, χ2 test, and GLM analysis.

Number of participants [N]
Age: years [mean (±SD)]
Sex: male [N (%)]
APOE ε4 carrier [N (%)]
MCA [mm/sec2, mean (±SD)]
MCV [mm/sec, mean (±SD)]
CV [mm/sec, mean (±SD)]
AMP [mm, mean (±SD)]

Healthy control
115
72.9 (±5.3)
56 (49)
27 (23)
31.12 (±6.56)
4.22 (±0.65)
3.02 (±0.49)
1.46 (±0.28)

Alzheimer’s disease
14
77.4 (±5.4)
10 (61)
12 (86)
26.84 (±4.23)
3.41 (±0.55)
2.53 (±0.44)
1.15 (±0.28)

p value
0.002~
0.11†
0.000001†
0.030‡
0.00045‡
0.0015‡
0.0030‡

~
Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered signiﬁcant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered signiﬁcant). ‡p value from generalised linear model analysis of diﬀerences between groups (including
signiﬁcant confounders). Bold values signiﬁcant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method. APOE ε4 carrier
status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. SD refers to standard deviation, mm refers to millimetres, sec refers to seconds, PFR refers to
pupil ﬂash response, HC refers to healthy control, AD refers to Alzheimer’s disease, GLM refers to generalised linear methods, MCA refers to maximum
constriction acceleration, MCV refers to maximum constriction velocity, CV refers to average constriction velocity, and AMP refers to constriction amplitude.

acceleration (MCA, mm/sec2) was calculated by masked
operators using fully automated computer algorithms. PFR
trials with artefacts or excessive blinking were discarded. A
computer algorithm was used to remove minor blinks.
2.5. Statistical Analysis. Descriptive statistics including
means and standard deviations (SD) for the full cohort and
clinical group are shown in Table 1. Demographic comparisons were performed using a χ2 test (Fisher’s exact calculation where necessary) for categorical variables (gender and
APOE ε4 status), and analysis of variance (ANOVA) for the
continuous age variable (p < 0 05 considered signiﬁcant).
Pupil response measures were compared between groups
using generalised linear modelling, with confounding variables reduced via the stepAIC method (a stepwise model
selection by Akaike information criterion). Confounders
considered included age, sex, and APOE ε4 status (the major
genetic risk factor for sporadic AD [30]). Statistical signiﬁcance was deﬁned as p < 0 05. All statistical analyses were
conducted in the R statistical environment [31]. The likelihood of false-positive results was minimised by comparing
p values to adjusted critical values according to the Benjamini
and Hochberg false discovery rate (FDR) method [32].
Receiver-operating characteristic (ROC) curve analysis was
also performed to further illustrate the classiﬁcation accuracy of the PFR parameters. The area under the curve
(AUC) of the ROC curves was estimated, an AUC of 1
indicates perfect classiﬁcation ability, whereas an AUC near
0.5 indicates poor (random) classiﬁcation ability. Logistical
models combining PFR measures were created to assess
combined classiﬁcation performance.

3. Results
Eligible AIBL participants in Perth with PET data available
numbered 206 (182 HC, 24 AD). N = 180 (87%) were willing
to participate in the pupillometry study. Participants were
excluded from the pupil response study if they had pupillary
malformations, severe cataract (N = 5), self-reported history
of glaucoma in either eye, penetrating eye wounds to both

eyes, and eye surgery to both eyes that involved the muscle;
if they used cholinesterase inhibitors or prescribed ocular
medications (N = 36); or if they were unable to complete
the task without excessive blinking (N = 10). All participants
were white Caucasians.
The pupillometry study thus included N = 129 participants (115 HC, 14 AD). Table 1 shows the demographic
comparisons between HC and AD groups, Table 2 shows
the same for the HC group stratiﬁed according to NAB
status, and Table 3 shows the same for the 37 HC participants
with longitudinal pupillometry results available, again stratiﬁed according to NAB status.
There was a signiﬁcantly greater proportion of APOE ε4
carriers in the AD group (Table 1, p = 0 000001), consistent
with APOE ε4 being the major genetic risk factor for sporadic
AD. The AD group was also older (mean age 77.4 years)
compared to the HC group (mean age 72.9 years) (p = 0 002).
PFR parameters were not signiﬁcantly diﬀerent between
males and females, or between APOE ε4 carriers and noncarriers, but they did exhibit an age dependence (MCV
p = 0 00002, CV p = 0 00001, MCA p = 0 002, and AMP
p = 0 02).
Signiﬁcant diﬀerences in pupil response were found
between the AD and HC groups (Table 1). Speciﬁcally, the
AD group exhibited reduced MCV (p = 0 00045, Figure 2),
AMP (p = 0 0030), MCA (p = 0 030), and CV (p = 0 0015).
All results were signiﬁcant after adjustment using the
Benjamini and Hochberg FDR method [32].
MCV provided the greatest clinical classiﬁcation accuracy with sensitivity 100%, speciﬁcity 67%, and AUC 0.85
(CI [0.76–0.93]). Combining PFR parameters into a logistic
model did not improve classiﬁcation performance, as the
parameters were highly correlated. However, adding age
and APOE є4 carrier status improved classiﬁcation performance to sensitivity 91.7%, speciﬁcity 93.1%, and AUC 0.94
(CI [0.87–1]).
Stratifying the HC group according to NAB, the lowNAB group consisted of 77 participants of mean age 72.3
years, while the high-NAB group consisted of 38 participants
of mean age 74.0 years. Demographics and results of this
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Table 2: Demographics and descriptive PFR analysis for the HC group stratiﬁed according to neocortical amyloid burden (NAB), with
ANOVA, χ2 test, and GLM analysis.

Number of participants [N]
Age: years [mean (±SD)]
Sex: male [N (%)]
APOE ε4 carrier: [N (%)]
MCA [mm/sec2, mean (±SD)]
MCV [mm/sec, mean (±SD)]
CV [mm/sec, mean (±SD)]
AMP [mean (±SD)]

Healthy control [low NAB]
77
72.3 (±5.2)
35 (49)
10 (13)
32.97 (±5.96)
4.48 (±0.63)
3.23 (±0.47)
1.54 (±0.29)

Healthy control [high NAB]
38
74.0 (±5.3)
20 (53)
17 (45)
30.08 (±7.2)
4.05 (±0.62)
2.92 (±0.42)
1.41 (±0.26)

p value
0.05734~
0.433†
0.000202†
0.067‡
0.021‡
0.12‡
0.77‡

~
Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered signiﬁcant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered signiﬁcant). ‡p value from the generalised linear model analysis of diﬀerences between groups
(including signiﬁcant confounders). Bold values signiﬁcant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method.
APOE ε4 carrier status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. NAB refers to neocortical amyloid burden, SD refers to standard
deviation, mm refers to millimetres, sec refers to seconds, PFR refers to pupil ﬂash response, HC refers to healthy control, AD refers to Alzheimer’s disease,
GLM refers to generalised linear methods, MCA refers to maximum constriction acceleration, MCV refers to maximum constriction velocity, CV refers to
average constriction velocity, and AMP refers to constriction amplitude.

Table 3: Demographics and descriptive PFR analysis for the longitudinal HC group stratiﬁed according to neocortical amyloid burden
(NAB), with ANOVA, χ2 test, and GLM and ROC analyses.

Number of participants [N]
Age: years [mean (±SD)]
Sex: male [N (%)]
APOE ε4 carrier [N (%)]
Change in MCA [mm/sec2, mean (±SD)]
Change in MCV [mm/sec, mean (±SD)]
Change in CV [mm/sec, mean (±SD)]
Change in AMP [mm, mean (±SD)]

Healthy control [low NAB]
19
72.2 (±0.31)
7 (37)
4 (21)
−1.49 (±1.80)
−0.19 (±0.17)
−0.52 (±0.75)
−0.24 (±0.32)

Healthy control [high NAB]
11
72.1 (±4.3)
8 (73)
10 (91)
−5.66 (±3.10)
−0.55 (±0.42)
−0.21 (±0.1)
−0.13 (±0.09)

p value
0.97~
0.00026†
0.035†
0.0068‡
0.047‡
0.62‡
0.24‡

~

Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered signiﬁcant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered signiﬁcant). ‡p value from the generalised linear model analysis of diﬀerences between groups
(including signiﬁcant confounders). Bold values signiﬁcant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method.
APOE ε4 carrier status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. NAB refers to neocortical amyloid burden, SD refers to standard
deviation, mm refers to millimetres, sec refers to seconds, PFR refers to pupil ﬂash response, HC refers to healthy control, AD refers to Alzheimer’s disease,
GLM refers to generalised linear methods, MCA refers to maximum constriction acceleration, MCV refers to maximum constriction velocity, CV refers to
average constriction velocity, and AMP refers to constriction amplitude.

comparison are presented in Table 2. There was a signiﬁcantly greater proportion of APOE ε4 carriers in the highNAB group (p = 0 0002), again consistent with APOE ε4
being the major genetic risk factor for sporadic AD. MCV
was reduced in the high-NAB group (p = 0 021). The remaining PFR parameters exhibited nonsigniﬁcant trends for
reduced values in the high-NAB group. Combining MCV
and MCA into a logistic model provided classiﬁcation accuracy for high NAB with sensitivity 57.1%, speciﬁcity 71.6%,
and AUC 0.63 (CI [0.52–0.75]). Adding age and APOE ε4
carrier status improved the performance of the model to sensitivity 60%, speciﬁcity 88%, and AUC 0.74 (CI [0.63–0.84]).
Thirty HC participants (19 low NAB, 11 high NAB)
underwent longitudinal pupillometry, with PFR data collected using the same device and an intermeasurement
period ranging 27–36 months prior to this study [8]. The
change in PFR parameters between visits was calculated.

Demographics and results of this comparison are presented in Table 3. There was again a signiﬁcantly greater
proportion of APOE ε4 carriers in the high-NAB group
(p = 0 035). The high-NAB group also had a greater percentage of males (73%) compared to the low-NAB group
(37%) (p = 0 00026). PFR parameters were not signiﬁcantly correlated with the exact interval between longitudinal measurements.
Group means for each PFR parameter change were
negative, indicating a weaker PFR at the more recent pupillometry test. The reduction in MCA and MCV was more
pronounced in the high-NAB group (p = 0 0068, p = 0 047,
resp.). The MCA result was still signiﬁcant after Benjamini
and Hochberg FDR adjustment [32]; however, the maximum velocity result was not. Combining MCA and MCV
in a logistic model provided a classiﬁcation accuracy for high
NAB with sensitivity 73%, speciﬁcity 100%, and AUC 0.90
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velocity in the constriction phase of the pupil ﬂash response. HC
refers to healthy control participants, AD refers to Alzheimer’s
disease, mm refers to millimetres, and sec refers to seconds.

(CI [0.75–1]). Adding age and APOE ε4 carrier status
improved the performance of the model to sensitivity 91%,
speciﬁcity 100%, and AUC 0.99 (CI [0.96–1.0]).

4. Discussion
The results are indicative of a weaker constriction phase pupil
response in AD, consistent with earlier studies [3–5, 9].
Possible causes of the PFR changes in AD are degeneration
in relays in the midbrain or central cholinergic depletion
[11, 12]. The four PFR parameters considered in this study
are all measures of the constriction phase of the PFR which
is primarily a parasympathetic cholinergic response [1].
These four PFR parameters were also the same parameters
that were most signiﬁcantly altered in AD in prior studies
[3–8]. The results therefore suggest cholinergic deﬁcits in
the peripheral parasympathetic pathway in AD. AD
patients receiving pharmacological treatment with anticholinesterase agents (such as Donepezil) have been excluded
from this study, due to the likely eﬀect of these drugs on
the PFR. The necessary exclusion of those on anticholinesterase agents introduces some bias as it is possible that
those not so treated are going to be diﬀerent in some way
from the 60–70% of AD subjects who do receive such
therapy; for example, reported results from other studies
indicate that Donepezil may normalize PFR in some AD
patients [4, 5]. If PFR changes in AD relate to neurotransmitter status, then PFR testing may be useful as an objective, noninvasive monitor with which to follow disease
progression and treatment eﬃcacy.
As therapeutic trials in AD have shifted to earlier,
preclinical intervention [33, 34], the need has grown for a
practical screening test to identify those individuals on the
pathway to symptomatic AD. Clinicopathologic studies at
autopsy support the hypothesis of a protracted asymptomatic
stage of AD, with the slow buildup of Aβ protein plaques
beginning about 10–20 years prior to diagnosis [35–41].
PET Aβ neuroimaging provides a semiquantitative measure
of NAB [16, 18–20]. However, while it is a valuable

diagnostic and secondary screening biomarker, the procedure is not suitable as a primary screening technology for
AD, due to cost, availability of PET scanners, invasiveness,
and radiation dose. There is consequently a need for a noninvasive, cost-eﬀective population-based AD screening technology to triage those requiring more extensive screening.
Recent results from Aβ immunotherapy trials have shown
promise, both for clearance of Aβ from the brain and
for slowing cognitive decline in early or preclinical AD
[33, 34], clearly underscoring the need for early detection.
To investigate pupillometry as a potential component of
such an AD screening test, the present study investigated
constriction phase pupil response in cognitively normal
healthy control individuals stratiﬁed according to PETdetermined NAB. The low-NAB group consists of cognitively and neuropathologically normal healthy control
participants, while the high-NAB group consists of participants who have AD neuropathology but are still cognitively
normal, suggesting they are in the preclinical phase of AD.
Since the cross-sectional data suggest a weaker pupil
response in the high-NAB group, we hypothesized that longitudinal monitoring of pupil response may perform better at
detecting preclinical AD. Natural variation in PFR between
individuals may limit the utility of a single PFR test for AD
screening; hence, it is possible that longitudinal monitoring
might facilitate more accurate preclinical detection or monitoring of AD. Hence, we also investigated longitudinal
changes in PFR over approximately 3 years. As the group
means for each PFR parameter change were negative, the
results suggested a decline in PFR over the period, consistent
with the observed age-dependence of PFR parameters in the
full cohort. The reduction in MCA was more pronounced in
the high-NAB group, with a similar trend for MCV (not
signiﬁcant after multiple testing adjustment). Longitudinal
change in MCA and MCV provided good classiﬁcation accuracy (AUC 0.9); hence, pupillometric changes over time may
have utility in detecting preclinical AD. The value of PFR
testing may be in its use for providing a noninvasive monitor
of physiological abnormality with which to follow disease
progression and treatment eﬃcacy.
Overall, the results add to the evidence of a weaker pupil
ﬂash response in AD and suggest that some PFR changes
may occur in preclinical AD. To our knowledge, we are the
only group to report on PFR diﬀerences with respect to
NAB and preclinical AD. Cholinergic depletion may occur
in preclinical AD, and pupillometry may have utility as a
component of a practical screening test for early detection
of AD. Additionally, longitudinal pupillometry could provide
a practical monitoring test for disease progression or
response to therapy.
The constriction phase of the PFR is primarily a parasympathetic response of the autonomic nervous system;
hence, constriction PFR parameters can be used as an accurate method to assess the function of the neurotransmitter
involved, acetylcholine [1, 3, 42]. Studies have suggested that
PFR is sensitive to early cholinergic depletion which can lead
to a decline in cognitive function. Cholinergic depletion may
also occur in other diseases such as Parkinson’s disease [43],
which has also been reported to inﬂuence PFR [5, 9]. Hence,
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the speciﬁcity of the PFR changes in AD needs further investigation using cohorts which include individuals with other
disorders that may aﬀect the cholinergic system and PFR.
A major strength of this study is the well characterized
cohorts, including the presence of neuroimaging data that
enable deeper interrogation of associations between PFR
parameters and AD. A limitation was the small number
of participants (N = 27) in the longitudinal study; the
results warrant further investigation with a similarly wellcharacterized, larger cohort.

5. Conclusions
This study demonstrates relationships between pupil
response parameters, neocortical amyloid plaque load, and
AD. Some PFR changes that are associated with diagnosed
AD also occur in preclinical AD.
Pupillometry demonstrates potential as an adjunct
(possibly together with blood or other biomarkers) (1) for
accurate diagnosis of AD and monitoring of disease progress
and response to therapy and (2) for low-cost and noninvasive
detection of preclinical AD, recruitment into preclinical
AD therapeutic trials and also monitoring response in
these trials.
The results of this study suggest that PFR monitoring,
rather than a single PFR test, might be more powerful as part
of an early screening test for AD and for monitoring disease
progress and response to intervention. Pupillometry is a
low-cost, noninvasive technology that may reﬂect early cholinergic deﬁcits preceding memory and cognitive decline.

Conflicts of Interest
All authors report no conﬂict of interest.

Acknowledgments
The authors wish to thank the Australian Imaging, Biomarker and Lifestyle (AIBL) Study Team (http://www.aibl.
csiro.au/about/aibl-research-team) for referring participants
to the study. They also wish to thank the participants of the
AIBL study for their commitment and dedication in helping
advance research into the early detection and causation of
AD. Funding for the study was provided by the CSIRO
Flagship Collaboration Fund and the Science and Industry
Endowment Fund (SIEF) in partnership with Edith Cowan
University (ECU), the Florey Institute of Neuroscience and
Mental Health, Alzheimer’s Australia (AA), National Ageing
Research Institute (NARI), Austin Health, CogState Ltd.,
Hollywood Private Hospital, and Sir Charles Gairdner
Hospital. The study also received funding from the National
Health and Medical Research Council (NHMRC), the
Dementia Collaborative Research Centres program (DCRC2),
the Cooperative Research Centre (CRC) for Mental Health—
funded through the CRC program (an Australian Government Initiative, Grant ID 20100104), the McCusker
Alzheimer’s Research Foundation, and Operational Infrastructure Support from the Government of Victoria. Shaun
Frost received funding support from the National Health

7
and Medical Research Council (NHMRC) of Australia, in
the form of a Dementia Research Fellowship.

References
[1] I. E. Loewenfeld, The Pupil: Anatomy, Physiology, and Clinical
Applications, 1999.
[2] H. Guyton, Textbook of Medical Physiology, W.B. Saunders
Company Publications, Philadelphia, 9th edition, 1996.
[3] D. F. Fotiou, C. G. Brozou, A. B. Haidich et al., “Pupil reaction
to light in Alzheimer’s disease: evaluation of pupil size changes
and mobility,” Aging Clinical and Experimental Research,
vol. 19, no. 5, pp. 364–371, 2007.
[4] F. Fotiou, K. N. Fountoulakis, M. Tsolaki, A. Goulas, and A.
Palikaras, “Changes in pupil reaction to light in Alzheimer’s
disease patients: a preliminary report,” International Journal
of Psychophysiology, vol. 37, no. 1, pp. 111–120, 2000.
[5] E. Granholm, S. Morris, D. Galasko, C. Shults, E. Rogers, and
B. Vukov, “Tropicamide eﬀects on pupil size and pupillary
light reﬂexes in Alzheimer’s and Parkinson’s disease,” International Journal of Psychophysiology, vol. 47, no. 2, pp. 95–115,
2003.
[6] E. Ferrario, M. Molaschi, L. Villa, O. Varetto, C. Bogetto,
and R. Nuzzi, “Is videopupillography useful in the diagnosis
of Alzheimer’s disease?” Neurology, vol. 50, no. 3, pp. 642–
644, 1998.
[7] A. Tales, T. Troscianko, D. Lush, J. Haworth, G. K. Wilcock,
and S. R. Butler, “The pupillary light reﬂex in aging and
Alzheimer’s disease,” Aging (Milano), vol. 13, no. 6,
pp. 473–478, 2001.
[8] S. Frost, Y. Kanagasingam, H. Sohrabi et al., “Pupil response
biomarkers for early detection and monitoring of Alzheimer’s
disease,” Current Alzheimer Research, vol. 10, no. 9, pp. 931–
939, 2013c.
[9] D. F. Fotiou, V. Stergiou, D. Tsiptsios, C. Lithari, M. Nakou,
and A. Karlovasitou, “Cholinergic deﬁciency in Alzheimer’s
and Parkinson’s disease: evaluation with pupillometry,” International Journal of Psychophysiology, vol. 73, no. 2, pp. 143–
149, 2009.
[10] P. Davies and A. J. Maloney, “Selective loss of central cholinergic neurons in Alzheimer’s disease,” Lancet, vol. 2, no. 8000,
p. 1403, 1976.
[11] K. Herholz, S. Weisenbach, G. Zündorf et al., “In vivo study of
acetylcholine esterase in basal forebrain, amygdala, and cortex
in mild to moderate Alzheimer disease,” NeuroImage, vol. 21,
no. 1, pp. 136–143, 2004.
[12] H. Tohgi, T. Abe, K. Hashiguchi, M. Saheki, and S. Takahashi,
“Remarkable reduction in acetylcholine concentration in the
cerebrospinal ﬂuid from patients with Alzheimer type dementia,” Neuroscience Letters, vol. 177, no. 1-2, pp. 139–142, 1994.
[13] R. Prettyman, P. Bitsios, and E. Szabadi, “Altered pupillary size
and darkness and light reﬂexes in Alzheimer’s disease,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 62, no. 6,
pp. 665–668, 1997.
[14] Alzheimer's Disease International, The Global Impact of
Dementia 2013–2050, 2013.
[15] K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal ﬂuid and plasma biomarkers in Alzheimer disease,”
Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010.
[16] A. M. Fagan, M. A. Mintun, R. H. Mach et al., “Inverse relation
between in vivo amyloid imaging load and cerebrospinal ﬂuid

8

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

Journal of Ophthalmology
Abeta42 in humans,” Annals of Neurology, vol. 59, no. 3,
pp. 512–519, 2006.
T. Sunderland, G. Linker, N. Mirza et al., “Decreased betaamyloid1-42 and increased tau levels in cerebrospinal ﬂuid of
patients with Alzheimer disease,” Journal of the American
Medical Association, vol. 289, no. 16, pp. 2094–2103, 2003.
L. J. Thal, K. Kantarci, E. M. Reiman et al., “The role of
biomarkers in clinical trials for Alzheimer disease,” Alzheimer
Disease and Associated Disorders, vol. 20, no. 1, pp. 6–15, 2006.
J. C. Morris, C. M. Roe, E. A. Grant et al., “Pittsburgh compound B imaging and prediction of progression from cognitive
normality to symptomatic Alzheimer disease,” Archives of
Neurology, vol. 66, no. 12, pp. 1469–1475, 2009.
C. C. Rowe, K. A. Ellis, M. Rimajova et al., “Amyloid imaging
results from the Australian Imaging, Biomarkers and Lifestyle
(AIBL) study of aging,” Neurobiology of Aging, vol. 31, no. 8,
pp. 1275–1283, 2010.
V. L. Villemagne, S. Burnham, P. Bourgeat et al., “Amyloid
beta deposition, neurodegeneration, and cognitive decline in
sporadic Alzheimer’s disease: a prospective cohort study,”
Lancet Neurology, vol. 12, no. 4, pp. 357–367, 2013.
K. A. Ellis, A. I. Bush, D. Darby et al., “The Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of aging: methodology
and baseline characteristics of 1112 individuals recruited for a
longitudinal study of Alzheimer’s disease,” International
Psychogeriatrics, vol. 21, no. 4, pp. 672–687, 2009.
G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price,
and E. M. Stadlan, “Clinical diagnosis of Alzheimer’s disease:
report of the NINCDS-ADRDA Work Group under the
auspices of Department of Health and Human Services Task
Force on Alzheimer’s disease,” Neurology, vol. 34, no. 7,
pp. 939–944, 1984.
R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G.
Tangalos, and E. Kokmen, “Mild cognitive impairment:
clinical characterization and outcome,” Archives of Neurology, vol. 56, no. 3, pp. 303–308, 1999.
B. Winblad, K. Palmer, M. Kivipelto et al., “Mild cognitive
impairment—beyond controversies, towards a consensus:
report of the International Working Group on Mild Cognitive
Impairment,” Journal of Internal Medicine, vol. 256, no. 3,
pp. 240–246, 2004.
P. Bourgeat, G. Chételat, V. L. Villemagne et al., “Beta-amyloid
burden in the temporal neocortex is related to hippocampal
atrophy in elderly subjects without dementia,” Neurology,
vol. 74, no. 2, pp. 121–127, 2010.
R. Vandenberghe, K. Van Laere, A. Ivanoiu et al., “18Fﬂutemetamol amyloid imaging in Alzheimer disease and mild
cognitive impairment: a phase 2 trial,” Annals of Neurology,
vol. 68, no. 3, pp. 319–329, 2010.
L. Thurfjell, J. Lilja, R. Lundqvist et al., “Automated quantiﬁcation of 18F-ﬂutemetamol PET activity for categorizing scans as
negative or positive for brain amyloid: concordance with visual
image reads,” Journal of Nuclear Medicine, vol. 55, no. 10,
pp. 1623–1628, 2014.
V. Villemagne, K. Pike, M. Fodero-Tavoletti et al., “Age
dependent prevalence of beta-amyloid positive 11C-PiB
PET in healthy elderly subjects parallels neuropathology
ﬁndings,” Journal of Nuclear Medicine, vol. 49, no. 5,
MeetingAbstracts_1, p. 34, 2008.
E. H. Corder, A. M. Saunders, W. J. Strittmatter et al., “Gene
dose of apolipoprotein E type 4 allele and the risk of

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

Alzheimer’s disease in late onset families,” Science, vol. 261,
no. 5123, pp. 921–923, 1993.
R_Development_Core_Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical
Computing, Vienna, Austria, 2013.
Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate - a practical and powerful approach to multiple testing,” Journal of Royal Statistical Society B Methodological,
vol. 57, no. 1, pp. 289–300, 1995.
J. Sevigny, P. Chiao, T. Bussière et al., “The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease,” Nature,
vol. 537, no. 7618, pp. 50–56, 2016.
B. Vellas, M. C. Carrillo, C. Sampaio et al., “Designing drug
trials for Alzheimer’s disease: what we have learned from
the release of the phase III antibody trials: a report from
the EU/US/CTAD task force,” Alzheimer's & Dementia,
vol. 9, no. 4, pp. 438–444, 2013.
H. Braak and E. Braak, “Frequency of stages of Alzheimerrelated lesions in diﬀerent age categories,” Neurobiology of
Aging, vol. 18, no. 4, pp. 351–357, 1997.
C. M. Hulette, K. A. Welsh-Bohmer, M. G. Murray, A. M.
Saunders, D. C. Mash, and L. M. McIntyre, “Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal
individuals,” Journal of Neuropathology and Experimental
Neurology, vol. 57, no. 12, pp. 1168–1174, 1998.
W. R. Markesbery, “Neuropathologic alterations in mild cognitive impairment: a review,” Journal of Alzheimers Disease,
vol. 19, no. 1, pp. 221–228, 2010.
W. R. Markesbery, F. A. Schmitt, R. J. Kryscio, D. G. Davis,
C. D. Smith, and D. R. Wekstein, “Neuropathologic substrate
of mild cognitive impairment,” Archives of Neurology-Chicago,
vol. 63, no. 1, pp. 38–46, 2006.
J. C. Morris and J. L. Price, “Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage
Alzheimer’s disease,” Journal of Molecular Neuroscience,
vol. 17, no. 2, pp. 101–118, 2001.
J. L. Price, A. I. Ko, M. J. Wade, S. K. Tsou, D. W. McKeel, and
J. C. Morris, “Neuron number in the entorhinal cortex and
CA1 in preclinical Alzheimer disease,” Archives of NeurologyChicago, vol. 58, no. 9, pp. 1395–1402, 2001.
T. GomezIsla, J. L. Price, D. W. McKeel, J. C. Morris, J. H.
Growdon, and B. T. Hyman, “Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease,”
Journal of Neuroscience, vol. 16, no. 14, pp. 4491–4500, 1996.
H. Wilhelm and B. Wilhelm, “Clinical applications of pupillography,” Journal of Neuro-Ophthalmology, vol. 23, no. 1,
pp. 42–49, 2003.
B. Dubois, B. Pillon, F. Lhermitte, and Y. Agid, “Cholinergic
deﬁciency and frontal dysfunction in Parkinson’s disease,”
Annals of Neurology, vol. 28, no. 2, pp. 117–121, 1990.

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Diabetes Research
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com

Disease Markers

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
https://www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Oncology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

AIDS

Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com

Research and Treatment
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

